Skip to main content

Advertisement

Table 3 SETBP1 mutations in atypical CML and unclassifiable MDS/MPN

From: SETBP1 mutations as a biomarker for myelodysplasia /myeloproliferative neoplasm overlap syndrome

  Reference Number of Patients Mutation Prevalence Impact on Survival
Atypical CML [34] 70 17 (24.3%) Yes (p-0.01)
[32] 60 19 (32.1%) No (p-0.191)
Unclassifiable MDS/MPN [34] 30 3 (10%) NR
[32] 240 20 (9.3%) NR
  1. NR Not reported